Pharma BD Deal Intelligence
Celgene Corporation / Jounce Therapeutics Inc.
2016 · Licensing/Option · $2.7B · Complete
Announcement Sentiment
38
Skeptical
Outcome Score
29
Did not work — the deal failed to deliver.
Celgene licensed Jounce Therapeutics' immuno-oncology pipeline including JTX-2011 ICOS agonist antibody, paying $261M upfront with up to $2.48B in milestones.
Key facts
Announced Feb 01, 2016 Closed Jul 19, 2016 Deal value $2.7B Deal type Licensing/Option Therapeutic area Oncology Indications Solid tumors Key assets JTX-2011 (vopratelimab) Mechanism ICOS agonist monoclonal antibody
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About